BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

GLOBAL BLOOD THERAPEUTICS — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Termination

GLOBAL BLOOD THERAPEUTICS

via KING & SPALDING LLP

3rd Quarter (July 1 - Sep 30) · 2021Posted Oct 20, 2021Filing document ↗LDA record ↗

Income$50Kfee reported

Client

Name: GLOBAL BLOOD THERAPEUTICS
Description: Biopharmaceutical Research Company
Location: California · United States of America

Registrant

Firm: KING & SPALDING LLP
Description: Law firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Policy issues related to access to innovative therapies, particularly focused on sickle cell disease
LobbyistsALLISON F KASSIR · KENDRICK B MEEK · AMIRAH SALAAM
Covered position (KENDRICK B MEEK): U.S. Representative (FL-17), 2002-2010
Covered position (AMIRAH SALAAM): Staff, Congressional Black Caucus - Rep. Meek (FL-17), Rep. Carson (IN-7), Rep. Payne, Sr. (NJ-10)
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.